Biomea Fusion

we are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. a covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. leveraging our extensive expertise in covalent binding chemistry and development, we built our proprietary fusion™ system platform to advance a pipeline of novel covalent therapies. our lead product candidate, bmf-219, is an orally bioavailable, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. beyond bmf-219, we are utilizing our novel platform to develop covalent treatments against other high-value oncogenic